{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:45:33Z","timestamp":1784684733967,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T00:00:00Z","timestamp":1100822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1007\/s00277-004-0974-4","type":"journal-article","created":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T09:32:16Z","timestamp":1100770336000},"page":"63-70","source":"Crossref","is-referenced-by-count":4,"title":["The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland"],"prefix":"10.1007","volume":"84","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,11,19]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1008273131598","volume":"9","author":"DC Betticher","year":"1998","unstructured":"Betticher DC, Ratschiller D, Hsu Schmitz SF, von Rohr A, Hess U, Zulian G. (1998) Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 9:721?726","journal-title":"Ann Oncol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/10428199809068575","volume":"29","author":"RC Chasty","year":"1998","unstructured":"Chasty RC, Myint H, Oscier DG, Orchard JA, Bussutil DP, Hamon MD, Prentice AG, Cooplestone J (1998) Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leuk Lymphoma 29:391?398","journal-title":"Leuk Lymphoma"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Vena DA, Barrett J, Freidlin B (1999) Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454?2460","journal-title":"J Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0959-8049(98)00140-3","volume":"34","author":"MA Fridrik","year":"1998","unstructured":"Fridrik MA, Jager G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubaur M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W (1998) Efficacy and toxicity of 2-chlorodeoxyadenosine 2-h infusion for 5 days as first-line treatment for advanced low grade non-Hodgkin?s lymphoma. Eur J Cancer 34:1560?1564","journal-title":"Eur J Cancer"},{"key":"CR5","first-page":"177","volume":"24","author":"J G\u00f3ra-Tybor","year":"1993","unstructured":"G\u00f3ra-Tybor J, Robak T (1993) Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 24:177?182","journal-title":"Acta Haematol Pol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.V79.4.888.bloodjournal794888","volume":"79","author":"G Juliusson","year":"1992","unstructured":"Juliusson G, Liliemark J (1992) Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2?deoxyadenosine (CdA): relation to opportunistic infections. Blood 79:888?894","journal-title":"Blood"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.0007-1048.2001.03296.x","volume":"116","author":"K Karisson","year":"2000","unstructured":"Karisson K, Stromberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A et al (2000) Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients and a long-term follow-up of 126 previously untreated patients. Br J Haematol 116:538?548","journal-title":"Br J Haematol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","volume":"81","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, O?Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ (1993) Long-term follow-up of patients with chronic lymphocytic leukaemia treated with fludarabine as a single agent. Blood 81:2878?2884","journal-title":"Blood"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","volume":"92","author":"MJ Keating","year":"1998","unstructured":"Keating MJ, O?Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H (1998) Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165?1171","journal-title":"Blood"},{"key":"CR10","first-page":"317","volume":"43","author":"E Krykowski","year":"1995","unstructured":"Krykowski E, Warzocha K, Robak T (1995) 2-chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia. Arch Immunol Ther Exp 43:317?321","journal-title":"Arch Immunol Ther Exp"},{"key":"CR11","first-page":"70","volume":"51","author":"J Liliemark","year":"1991","unstructured":"Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2?-deoxyadenosine in humans. Cancer Res 51:70?72","journal-title":"Cancer Res"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncr.11000","volume":"97","author":"M Montillo","year":"2003","unstructured":"Montillo M, Tedeschi A, O?Brien S, Di Raimondo F, Lerner S, Ferajoli A, Morra E, Keating MJ (2003) Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97:114?120","journal-title":"Cancer"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","volume":"19","author":"SM O?Brien","year":"2001","unstructured":"O?Brien SM, Kantarjian HH, Cortes J, Beran M, Koller C, Giles FI, Lerner S, Keating M (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414?1420","journal-title":"J Clin Oncol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","volume":"72","author":"LD Piro","year":"1988","unstructured":"Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069?1073","journal-title":"Blood"},{"issue":"suppl 1","key":"CR15","first-page":"429a","volume":"92","author":"C Pocock","year":"1998","unstructured":"Pocock C, Matutes E, Wotherspoon A, Cunnigham D, Catovsky D (1998) Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma (abstract 1774). Blood 92 [Suppl 1]:429a","journal-title":"Blood"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/10428190109097654","volume":"40","author":"T Robak","year":"2001","unstructured":"Robak T (2001) Cladribine in the treatment of chronic lymphocytic leukaemia. Leuk Lymphoma 40:551?564","journal-title":"Leuk Lymphoma"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0609.1997.tb00933.x","volume":"58","author":"T Robak","year":"1997","unstructured":"Robak T, B?asi?ska-Morawiec M, Krykowski E, Hellmann A, Konopka L (1997) Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Eur J Haematol 58:109?113","journal-title":"Eur J Haematol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428199909083391","volume":"34","author":"T Robak","year":"1999","unstructured":"Robak T, B?asi?ska-Morawiec M, B?o?ski JZ., Dmoszy?ska A (1999) 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 34:151?157","journal-title":"Leuk Lymphoma"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0959-8049(97)00349-3","volume":"33","author":"T Robak","year":"1997","unstructured":"Robak T, B?asi?ska-Morawiec M, B?o?ski JZ, Krykowski E, Komarnicki M, Trepi?ska E, Kazimierczuk M, Hansz J, Dmoszy?ska A, Roli?ski J, Konopka L, Skotnicki AB, Nowak WS, Kotlarek-Haus S, Zdziarska B, Urasi?ski I (1997) The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. Eur J Cancer 33:2347?2351","journal-title":"Eur J Cancer"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1997.tb00980.x","volume":"59","author":"T Robak","year":"1997","unstructured":"Robak T, B?asi?ska-Morawiec M, Krykowski E, Hellmann A, Lewandowski K, Dmoszy??ka A, Adamczyk-Cioch M, Kazimierczak M, Trepi?ska E, Dwilewicz-Trojaczek M, Kuratowska Z, Skotnicki AB, Nowak WS, Zdziarska B, Urasi?ski I (1997) 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases. Eur J Haematol 59:216?220","journal-title":"Eur J Haematol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/10428199609051736","volume":"22","author":"T Robak","year":"1996","unstructured":"Robak T, B?asi?ska-Morawiec M, Krykowski E, Kasznicki M, P?u?a?ska A, Petoemski P, Hellmann A, Zaucha JM, Lewandowski K, Dmoszy?ska A, Hansz J, Komarnicki M, Konopka L, Dur?y?ski T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasi?ski I, Zdziarska B, Maj S, Kope? I, Skotnicki AB, Dwilewicz-Trojaczek J, Kuratowska Z, Grieb P (1996) Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 22:509?514","journal-title":"Leuk Lymphoma"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10428199609051736","volume":"22","author":"T Robak","year":"1996","unstructured":"Robak T, B?asi?ska-Morawiec M, Krykowski E., Hansz J, Komarnicki M, Kazimierczak M, Konopka L, Maj S, Hellmann A, Zaucha JM, Urasi?ski I, Zdziarska B, Kotlarek-Haus S, Usnarska-Zubkiewicz L, Kuratowska Z, Dwilewicz-Trojaczek J, Ho?owiecki J, Krawczyk-Kuli? M, Grieb P (1996) 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 22:107?111","journal-title":"Leuk Lymphoma"},{"key":"CR23","first-page":"285","volume":"23","author":"T Robak","year":"1992","unstructured":"Robak T, B?asi??ka-Morawiec M, Krykowski E (1992) Transient eosinophilia in a patient with hairy cell leukaemia treated with 2-chlorodeoxyadenosine. Acta Haematol Pol 23:285?290","journal-title":"Acta Haematol Pol"},{"key":"CR24","first-page":"2723","volume":"96","author":"T Robak","year":"2000","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, B?asi?ska-Morawiec M, Krykowski E, Dmoszy?ska A, Mruga?a-?piewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasi?ski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective randomized, multicenter trial. Blood 96:2723?2729","journal-title":"Blood"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejca.2003.09.031","volume":"40","author":"T Robak","year":"2004","unstructured":"Robak T, Blo?ski JZ, G\u00f3ra-Tybor J, Kasznicki M, Konopka L, Ceglarek B, Komarnicki M, Lewandowski K, Hellmann A, Lewandowski K, Moskwa A, Dmoszy??ka A, Soko?owska B, Dwilewicz-Trojaczek A, Tomaszewska A, Su?ek K, Ca?becka M (2004) Second malignancies and Richter?s syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 40:383?389","journal-title":"Eur J Cancer"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.thj.6200191","volume":"3","author":"T Robak","year":"2002","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, G\u00f3ra-Tybor J, Dwilewicz-Trojaczek J, Stella-Ho?owiecka B, Wo?owiec D (2002) Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 3:244?250","journal-title":"Hematol J"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.leu.2402216","volume":"15","author":"T Robak","year":"2001","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, G\u00f3ra-Tybor J, Dwilewicz-Trojaczek J, Boguradzki P, Konopka L, Ceglarek B, Su?ek J, Kuliczkowski K, Wo?owiec D, Stella-Ho?owiecka B, Skotnicki AB, Nowak W, Moskwa-Sroka B, Dmoszy?ska A, Ca?becka M (2001) Cladribine combined with mitoxantrone and cyclophosphamide as front-line therapy in chronic lymphocytic leukemia. Leukemia 15:1510?1516","journal-title":"Leukemia"},{"issue":"suppl 2","key":"CR28","first-page":"S44","volume":"44","author":"T Robak","year":"2003","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, G\u00f3ra-Tybor J, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszy??ka A, Kowal M, Ca?becka M, Zawilska K, Stella-Ho?owiecka B, Su?ek K, Gawro?ski K, Kuliczkowski K, Potoczek S, K?oczko J, Jeromin J, Warzocha K (2003) Comparison of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone in previously untreated B-CLL patients: an updated report of a randomized study (abstract 78). Leuk Lymphoma 44 [Suppl 2]:S44","journal-title":"Leuk Lymphoma"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1034\/j.1600-0609.2002.02711.x","volume":"69","author":"T Robak","year":"2002","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, G\u00f3ra-Tybor J, Hellmann A, Konopka L, Dmoszy??ka A, Dwilewicz-Trojaczek J, Wo?owiec D (2002) Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. Eur J Haematol 69:27?36","journal-title":"Eur J Haematol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2000.01850.x","volume":"108","author":"T Robak","year":"2000","unstructured":"Robak T, B?o?ski JZ, Kasznicki M, Konopka L, Ceglarek B, Dmoszy?ska A, Soroka-Wojtaszko M, Skotnicki AB, Nowak W, Dwilewicz-Trojaczek J, Tomaszewska A, Hellmann A, Lewandowski K, Kuliczkowski K, Potoczek S, Zdziarska B, Hansz J, Kroll R, Komarnicki M, Ho?owiecki J, Grieb P (2000) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia-updated results of the multicentre study of 378 patients. Br J Haematol 108:357?368","journal-title":"Br J Haematol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","volume":"13","author":"T Robak","year":"1999","unstructured":"Robak T, B?o?ski JZ, Urba?ska-Ry? H, B?asi?ska-Morawiec M, Skotnicki AB (1999) 2-chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 13:518?523","journal-title":"Leukemia"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2001.00303.x","volume":"66","author":"T Robak","year":"2001","unstructured":"Robak T, G\u00f3ra-Tybor J, Lech-Mara?da E, B?o?ski JZ, Kasznicki M (2001) Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 66:188?194","journal-title":"Eur J Haematol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428190109099341","volume":"42","author":"T Robak","year":"2001","unstructured":"Robak T, Kasznicki M, Bartkowiak J, Kordek R, Wawrzyniak E, B?o?ski JZ (2001) Richter?s syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur. Leuk Lymphoma 42:789-796","journal-title":"Leuk Lymphoma"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1046\/j.1365-2141.2001.02622-2.x","volume":"112","author":"T Robak","year":"2001","unstructured":"Robak T, Kasznicki M, B?o??ki JZ, Dmoszy?ska A, Skotnicki AB (2001) Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine. Br J Haematol 112:1083?1085","journal-title":"Br J Haematol"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","volume":"16","author":"T Robak","year":"2002","unstructured":"Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 16:1015?1027","journal-title":"Leukemia"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1042819032000159825","volume":"45","author":"T Robak","year":"2004","unstructured":"Robak T, Smolewski P, Urba?ska-Ry? H, G\u00f3ra-Tybor J, B?o?ski JZ, Kasznicki M (2004) Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 45:937?944","journal-title":"Leuk Lymphoma"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/1042819031000063417","volume":"44","author":"T Robak","year":"2003","unstructured":"Robak T, Szmigielska-Kap?on A, Smolewski P, Wawrzyniak E, Korycka A, Bartkowiak J, Kordek R (2003) Hodgkin?s type of Richter?s syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide. Leuk Lymphoma 44:859?866","journal-title":"Leuk Lymphoma"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0609.2001.00592.x","volume":"67","author":"T Robak","year":"2001","unstructured":"Robak T, Urba??ka-Ry? H, Strzelecka B, Krykowski E, Bartkowiak J, B?o?ski JZ, Kordek R, Warzocha K (2001) Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter?s syndrome. Eur J Haematol 67:322?327","journal-title":"Eur J Haematol"},{"issue":"suppl 5","key":"CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199109103394","volume":"16","author":"A Saven","year":"1991","unstructured":"Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. Leuk Lymphoma 16 [Suppl 5]:133?138","journal-title":"Leuk Lymphoma"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/07357909309011674","volume":"11","author":"A Saven","year":"1993","unstructured":"Saven A, Piro LD (1993) 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia. Cancer Invest 11:559?564","journal-title":"Cancer Invest"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","volume":"83","author":"JF Seymour","year":"1994","unstructured":"Seymour JF, Kurzrock R, Freireich EJ, Estey EH (1994) 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906?2911","journal-title":"Blood"},{"issue":"suppl 1","key":"CR42","first-page":"387a","volume":"100","author":"P Smolewski","year":"2002","unstructured":"Smolewski P, Szmigielska A, Cebula B, Sobczak A, Dar?ynkiewicz Z, Robak T (2002) Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-CLL chronic lymphocytic leukemia cells measured by fluorochrome labeled inhibitors of caspases (FLICA) assay (abstract 1503). Blood 100 [Suppl 1]:387a","journal-title":"Blood"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1034\/j.1600-0609.2002.01598.x","volume":"68","author":"A Szmigielska-Kap?on","year":"2002","unstructured":"Szmigielska-Kap?on A, Ciesielska E, Szmigiero L, Robak T (2002) Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 68:370?375","journal-title":"Eur J Haematol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V86.7.2463.2463","volume":"86","author":"MS Tallman","year":"1995","unstructured":"Tallman MS, Hakimian D (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 86:2463?2474","journal-title":"Blood"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.leu.2401431","volume":"13","author":"E Neste van Den","year":"1999","unstructured":"van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gills E, Leveugle P, Deneys L, Ferrant A, Van den Gerghe G (1999) Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2?deoxyadenosine. Leukemia 13:918?925","journal-title":"Leukemia"},{"key":"CR46","first-page":"268","volume":"105","author":"E Neste van Den","year":"1999","unstructured":"van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A (1999) Myelodysplastic syndrome with monosomy 5 and\/or 7 following therapy with 2-chloro-2?-deoxyadenosine. Br J Haematol 105:268?270","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-004-0974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-004-0974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-004-0974-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T05:09:12Z","timestamp":1585976952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-004-0974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,19]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s00277-004-0974-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,19]]}}}